---
document_datetime: 2023-09-21 21:22:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/glubrava-epar-procedural-steps-taken-authorisation_en.pdf
document_name: glubrava-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3994685
conversion_datetime: 2025-12-15 00:28:19.824128
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Takeda Global Research and Development Centre (Europe) Ltd. submitted on 17 July 2007  an  application  for  Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for Pioglitazone  /  metformin  hydrochloride  Takeda  15  mg/850  mg  film-coated  tablets,  through  the centralised procedure according to Regulation (EC) No 726/2004.

The  legal  basis  for  this  application  refers  to  Article  10(c)  of  Directive  2001/83/EC,  as  amended, relating  to  informed  consent  from  the  marketing  authorisation  holder,  Takeda  Global  Research  and Development Centre (Europe) Ltd, for the authorised medicinal product Competact (EU/1/06/354/001-009).

<!-- image -->

Scientific Advice: The applicant did not seek scientific advice at the CHMP. Licensing status: The initial product, Competact, has been given a Community Marketing Authorisation on 28 July 2006. The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Patrick Salmon (IRL) Co-Rapporteur: Concepcion Prieto Yerro (ES) 2. Steps taken for the assessment of the product · The application was received by the EMEA on 17 July 2007. · The procedure started on 23 July 2007. · The Rapporteur's first Assessment Report was circulated to all CHMP members on 24 August 2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 27 August 2007. · During  the  meeting  on  17  -  20  September  2007,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting  a  Marketing  Authorisation  to  Pioglitazone  /  metformin  hydrochloride  Takeda  15 mg/850 mg film-coated tablets on 20 September 2007. · The CHMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 11 December 2007. Medicinal Product no longer authorised